Difference between revisions of "Breast cancer, PIK3CA-mutated"
Jump to navigation
Jump to search
Line 29: | Line 29: | ||
|2015-2017 | |2015-2017 | ||
| style="background-color:#1a9851" |Phase III (E-RT-esc) | | style="background-color:#1a9851" |Phase III (E-RT-esc) | ||
− | |Fulvestrant | + | |[[#Fulvestrant_monotherapy|Fulvestrant]] |
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
|- | |- |
Revision as of 00:31, 21 April 2021
3 regimens on this page
3 variants on this page
|
Note: this page has regimens which are specific to breast cancer that is PIK3CA-mutated. Please see the main breast cancer page for other chemotherapy regimens.
Advanced or metastatic disease, all lines of therapy
Alpelisib & Fulvestrant
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
André et al. 2019 (SOLAR-1) | 2015-2017 | Phase III (E-RT-esc) | Fulvestrant | Superior PFS |
Note: patients enrolled in this trial had HR-positive breast cancer.
Targeted therapy
- Alpelisib (Piqray) 300 mg PO once per day
Hormonotherapy
- Fulvestrant (Faslodex) as follows:
- Cycle 1: 500 mg IM once per day on days 1 & 15
- Cycle 2 onwards: 500 mg IM once on day 1
28-day cycles
References
- SOLAR-1: André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. link to original article contains verified protocol PubMed NCT02437318
Fulvestrant monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
André et al. 2019 (SOLAR-1) | 2015-2017 | Phase III (C) | Alpelisib & Fulvestrant | Inferior PFS |
Dent et al. 2020 (SANDPIPER) | 2015-2017 | Phase III (C) | Taselisib & Fulvestrant | Inferior PFS |
Note: patients enrolled in these trials had HR-positive breast cancer.
Hormonotherapy
- Fulvestrant (Faslodex) as follows:
- Cycle 1: 500 mg IM once per day on days 1 & 15
- Cycle 2 onwards: 500 mg IM once on day 1
28-day cycles
References
- SOLAR-1: André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. link to original article contains verified protocol PubMed NCT02437318
- SANDPIPER: Dent S, Cortés J, Im YH, Diéras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, He J, De Laurentiis M, Sousa S, Drullinsky P, Jacot W. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021 Feb;32(2):197-207. Epub 2020 Nov 10. link to original article PubMed NCT02340221